title: An Open-labeled, Multicenter Phase II Study of Tamibarotene in Patients with Steroid-refractory Chronic Graft-versus-Host Disease.
abstract: Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
authors: Department of Hematology and Oncology, Okayama University Hospital, Okayama 700-8558, Japan.yosmaeda@md.okayama-u.ac.jp.
authors: Yoshinobu
authors: Y
authors: Maeda
authors: Hisakazu
authors: H
authors: Nishimori
authors: Yoshihiro
authors: Y
authors: Inamoto
authors: Hirohisa
authors: H
authors: Nakamae
authors: Masashi
authors: M
authors: Sawa
authors: Yasuo
authors: Y
authors: Mori
authors: Kazuteru
authors: K
authors: Ohashi
authors: Shin-Ichiro
authors: SI
authors: Fujiwara
authors: Mitsune
authors: M
authors: Tanimoto
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002908:Chronic Disease; D002985:Clinical Protocols; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
chemical_list: D000305:Adrenal Cortex Hormones; D001565:Benzoates; D007166:Immunosuppressive Agents; D013764:Tetrahydronaphthalenes; C061133:tamibarotene